In this article, we will explore Lexatumumab from different perspectives and in various contexts. We will delve into its history, its origins, its influence on society and its relevance today. We will analyze Lexatumumab from a multidisciplinary approach, addressing cultural, social, political, economic and scientific aspects. Through this journey, we aim to offer a comprehensive and complete vision of Lexatumumab, providing the reader with a deep and enriching understanding of this topic.
Monoclonal antibody | |
---|---|
Type | Whole antibody |
Source | Human |
Target | TRAIL-R2 |
Clinical data | |
ATC code |
|
Identifiers | |
CAS Number | |
ChemSpider |
|
UNII | |
KEGG | |
Chemical and physical data | |
Formula | C6346H9832N1720O2002S42 |
Molar mass | 143601.02 g·mol−1 |
(what is this?) (verify) |
Lexatumumab (also known as ETR2-ST01) is an experimental agonistic human monoclonal antibody against TRAIL-R2 (DR5, APO-2), intended for the treatment of cancer.
HGS-ETR2 antibodies were generated by Human Genome Sciences through a collaboration with Cambridge Antibody Technology.
Development was discontinued in 2015.